Cargando…
The Fatty Acid Lipid Metabolism Nexus in COVID-19
Enteric symptomology seen in early-stage severe acute respiratory syndrome (SARS)-2003 and COVID-19 is evidence of virus replication occurring in the intestine, liver and pancreas. Aberrant lipid metabolism in morbidly obese individuals adversely affects the COVID-19 immune response and increases di...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826519/ https://www.ncbi.nlm.nih.gov/pubmed/33440724 http://dx.doi.org/10.3390/v13010090 |
_version_ | 1783640539911946240 |
---|---|
author | Tanner, Jerome E. Alfieri, Caroline |
author_facet | Tanner, Jerome E. Alfieri, Caroline |
author_sort | Tanner, Jerome E. |
collection | PubMed |
description | Enteric symptomology seen in early-stage severe acute respiratory syndrome (SARS)-2003 and COVID-19 is evidence of virus replication occurring in the intestine, liver and pancreas. Aberrant lipid metabolism in morbidly obese individuals adversely affects the COVID-19 immune response and increases disease severity. Such observations are in line with the importance of lipid metabolism in COVID-19, and point to the gut as a site for intervention as well as a therapeutic target in treating the disease. Formation of complex lipid membranes and palmitoylation of coronavirus proteins are essential during viral replication and assembly. Inhibition of fatty acid synthase (FASN) and restoration of lipid catabolism by activation of AMP-activated protein kinase (AMPK) impede replication of coronaviruses closely related to SARS-coronavirus-2 (CoV-2). In vitro findings and clinical data reveal that the FASN inhibitor, orlistat, and the AMPK activator, metformin, may inhibit coronavirus replication and reduce systemic inflammation to restore immune homeostasis. Such observations, along with the known mechanisms of action for these types of drugs, suggest that targeting fatty acid lipid metabolism could directly inhibit virus replication while positively impacting the patient’s response to COVID-19. |
format | Online Article Text |
id | pubmed-7826519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78265192021-01-25 The Fatty Acid Lipid Metabolism Nexus in COVID-19 Tanner, Jerome E. Alfieri, Caroline Viruses Review Enteric symptomology seen in early-stage severe acute respiratory syndrome (SARS)-2003 and COVID-19 is evidence of virus replication occurring in the intestine, liver and pancreas. Aberrant lipid metabolism in morbidly obese individuals adversely affects the COVID-19 immune response and increases disease severity. Such observations are in line with the importance of lipid metabolism in COVID-19, and point to the gut as a site for intervention as well as a therapeutic target in treating the disease. Formation of complex lipid membranes and palmitoylation of coronavirus proteins are essential during viral replication and assembly. Inhibition of fatty acid synthase (FASN) and restoration of lipid catabolism by activation of AMP-activated protein kinase (AMPK) impede replication of coronaviruses closely related to SARS-coronavirus-2 (CoV-2). In vitro findings and clinical data reveal that the FASN inhibitor, orlistat, and the AMPK activator, metformin, may inhibit coronavirus replication and reduce systemic inflammation to restore immune homeostasis. Such observations, along with the known mechanisms of action for these types of drugs, suggest that targeting fatty acid lipid metabolism could directly inhibit virus replication while positively impacting the patient’s response to COVID-19. MDPI 2021-01-11 /pmc/articles/PMC7826519/ /pubmed/33440724 http://dx.doi.org/10.3390/v13010090 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tanner, Jerome E. Alfieri, Caroline The Fatty Acid Lipid Metabolism Nexus in COVID-19 |
title | The Fatty Acid Lipid Metabolism Nexus in COVID-19 |
title_full | The Fatty Acid Lipid Metabolism Nexus in COVID-19 |
title_fullStr | The Fatty Acid Lipid Metabolism Nexus in COVID-19 |
title_full_unstemmed | The Fatty Acid Lipid Metabolism Nexus in COVID-19 |
title_short | The Fatty Acid Lipid Metabolism Nexus in COVID-19 |
title_sort | fatty acid lipid metabolism nexus in covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826519/ https://www.ncbi.nlm.nih.gov/pubmed/33440724 http://dx.doi.org/10.3390/v13010090 |
work_keys_str_mv | AT tannerjeromee thefattyacidlipidmetabolismnexusincovid19 AT alfiericaroline thefattyacidlipidmetabolismnexusincovid19 AT tannerjeromee fattyacidlipidmetabolismnexusincovid19 AT alfiericaroline fattyacidlipidmetabolismnexusincovid19 |